drugset / Trial / NCT04999761
AB122 Platform Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zimberelimab | Monoclonal antibody | 240 unknown | — |
| Subject | Zimberelimab | Monoclonal antibody | 360 unknown | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Background | Domvanalimab | Monoclonal antibody | 1200 unknown | — |
| Background | Futibatinib | Small molecule | — | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Nab-paclitaxel | Small molecule | 100 mg/m2 | — |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |
| Background | Ramucirumab | Monoclonal antibody | — | — |
| Background | TAS-102 | Small molecule | — | Oral |
| Background | TAS-115 | Small molecule | — | Oral |
| Background | TAS-116 | Small molecule | — | Oral |
| Background | fluorouracil | Small molecule | 800 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 1000 mg/m2 | Intravenous |